Pulmonary arterial hypertension (PAH) is a rare, chronic disease of the pulmonary vasculature that is associated with poor outcomes. Its pathogenesis is multifactorial and includes micro-RNA (miRNA) deregulation. The understanding of the role of miRNAs in PAH is expanding quickly, and it is increasingly difficult to identify which miRNAs have the highest translational potential. This review summarizes the current knowledge of miRNA expression in PAH, discusses the challenges in miRNA analysis and interpretation, and highlights 4 promising miRNAs in this field (miR-29, miR-124, miR-140, and miR-204)
Pulmonary Arterial hypertension (PAH) is a devastating progressive disease that significantly decrea...
Over the last years, small non-coding microRNAs (miRNAs) have emerged as central actors of PAH etiol...
MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare but life shortening disease, the diagnos...
MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare but life shortening disease, the diagnos...
BACKGROUNDThe dysregulation of microRNA (miRNA) is known to contribute to the pathobiology of pulmon...
Since the first descriptions of their active functions more than ten years ago, small non-coding RNA...
Rationale: MicroRNAs (miRNAs or miRs) are implicated in the pathogenesis of various cardiovascular d...
PULMONARY ARTERIAL HYPERTENSION (PAH) is a progressive dis-ease manifested by maladaptation of the p...
Pulmonary hypertension (PH) is a pathological disorder with multiple clinical manifestations that le...
Pulmonary arterial hypertension (PAH) is characterized by a progressive elevation of pulmonary press...
Pulmonary arterial remodeling is a presently irreversible pathologic hallmark of pulmonary arterial ...
Pulmonary arterial hypertension (PAH) is characterized by a progressive elevation of pulmonary press...
Pulmonary hypertension (PH), a heterogeneous vascular disease, consists of subtypes with overlapping...
Pulmonary Arterial hypertension (PAH) is a devastating progressive disease that significantly decrea...
Over the last years, small non-coding microRNAs (miRNAs) have emerged as central actors of PAH etiol...
MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare but life shortening disease, the diagnos...
MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and...
BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare but life shortening disease, the diagnos...
BACKGROUNDThe dysregulation of microRNA (miRNA) is known to contribute to the pathobiology of pulmon...
Since the first descriptions of their active functions more than ten years ago, small non-coding RNA...
Rationale: MicroRNAs (miRNAs or miRs) are implicated in the pathogenesis of various cardiovascular d...
PULMONARY ARTERIAL HYPERTENSION (PAH) is a progressive dis-ease manifested by maladaptation of the p...
Pulmonary hypertension (PH) is a pathological disorder with multiple clinical manifestations that le...
Pulmonary arterial hypertension (PAH) is characterized by a progressive elevation of pulmonary press...
Pulmonary arterial remodeling is a presently irreversible pathologic hallmark of pulmonary arterial ...
Pulmonary arterial hypertension (PAH) is characterized by a progressive elevation of pulmonary press...
Pulmonary hypertension (PH), a heterogeneous vascular disease, consists of subtypes with overlapping...
Pulmonary Arterial hypertension (PAH) is a devastating progressive disease that significantly decrea...
Over the last years, small non-coding microRNAs (miRNAs) have emerged as central actors of PAH etiol...
MicroRNAs (miRNAs) have emerged as a new class of posttranscriptional regulators of many cardiac and...